Skip to main content
Leonora R. Slatnick

Leonora R. Slatnick, MD

Languages spoken: English, Spanish

Clinical Locations

University of Utah Hospital

University Pediatric Clinic
Salt Lake City
801-581-2205
  • Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

    She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

    Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

    Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

    Board Certification

    American Board of Pediatrics (Pediatrics)
    National Board of Medical Examiners
  • Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

    She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

    Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

    Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    National Board of Medical Examiners

    Education history

    Fellowship Pediatric Hematology-Oncology - University of Colorado School of Medicine Fellow
    Clinical Sciences - University of Colorado Anschutz Medical Campus M.S.
    Residency Pediatrics - University of Colorado School of Medicine Resident
    Pediatrics - University of Colorado School of Medicine Intern
    Professional Medical Medicine - University of Texas Southwestern Medical School M.D.
    Study Abroad Spanish Curriculum - Universidad de Salamanca
    Undergraduate Major: Cell Biology and Neuroscience; Minors: Spanish Language, Psychology - Rutgers University B.S.

    Selected Publications

    Journal Article

    1. Slatnick LR, Jimeno A, Gore L, Macy ME (2021). Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc), 57(11), 677-688. (Read full article)
    2. Slatnick LR, Thornhill D, Deakyne Davies SJ, Ford JB, Scott HF, Manco-Johnson MJ, Warren BB (2020). Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. J Pediatr, 225, 198-206.e2. (Read full article)
  • News & Podcasts